Literature DB >> 23194833

Clopidogrel resistance is associated with thromboembolic complications in patients undergoing neurovascular stenting.

J T Fifi1, C Brockington, J Narang, W Leesch, S L Ewing, H Bennet, A Berenstein, J Chong.   

Abstract

BACKGROUND AND
PURPOSE: Antiplatelet drug resistance has been associated with thromboembolic complications in patients after coronary stent placement. It has not been well-studied in patients who have neurovascular stent-placement procedures. This study aimed to analyze the relationship between antiplatelet drug resistance and neurovascular stent-placement complications.
MATERIALS AND METHODS: A prospective data base of all patients treated at our institution was used to identify patients with neurovascular stent-placement procedures. During a 4.5-year period, all patients undergoing neurovascular stent placement were evaluated for aspirin and clopidogrel resistance by using the VerifyNow assay. During an observational phase, all patients received 75 mg of clopidogrel and aspirin (group A). During the intervention phase (group B), patients were given additional clopidogrel on the basis of the clopidogrel resistance assay. We assessed the development of thromboembolic complications within 30 days of the procedure in patients who were resistant-versus-nonresistant to clopidogrel.
RESULTS: Of 96 patients who had neurovascular stent placement, 5.2% were resistant to aspirin and 36.5% were resistant to clopidogrel. Periprocedural thromboembolic complications were seen in 7 patients (7.3%). In a multivariate logistic regression model, clopidogrel resistance, higher diastolic blood pressure, and lack of statin use were significantly associated with periprocedural thromboembolic complication. There was a nonsignificant decrease in thromboembolic complications in patients whose clopidogrel dosage was tailored to the assay.
CONCLUSIONS: In our series, clopidogrel resistance was associated with increased periprocedural thromboembolic complications from neurovascular stent-placement procedures. Targeting the clopidogrel dose to platelet inhibition assays may improve clinical outcomes and requires further study.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23194833      PMCID: PMC7964502          DOI: 10.3174/ajnr.A3405

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  28 in total

1.  Onset and offset of platelet inhibition after high-dose clopidogrel loading and standard daily therapy measured by a point-of-care assay in healthy volunteers.

Authors:  Matthew J Price; Jacqueline L Coleman; Steven R Steinhubl; Garrett B Wong; Christopher P Cannon; Paul S Teirstein
Journal:  Am J Cardiol       Date:  2006-07-07       Impact factor: 2.778

2.  High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention.

Authors:  Nicoline J Breet; Jochem W van Werkum; Heleen J Bouman; Johannes C Kelder; Ankie M Harmsze; Christian M Hackeng; Jurriën M ten Berg
Journal:  Heart       Date:  2011-04-08       Impact factor: 5.994

3.  Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease.

Authors:  Jessica L Mega; Willibald Hochholzer; Andrew L Frelinger; Michael J Kluk; Dominick J Angiolillo; Dean J Kereiakes; Steven Isserman; William J Rogers; Christian T Ruff; Charles Contant; Michael J Pencina; Benjamin M Scirica; Janina A Longtine; Alan D Michelson; Marc S Sabatine
Journal:  JAMA       Date:  2011-11-16       Impact factor: 56.272

4.  Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance.

Authors:  Eli I Lev; Rajnikant T Patel; Kelly J Maresh; Sasidhar Guthikonda; Juan Granada; Timothy DeLao; Paul F Bray; Neal S Kleiman
Journal:  J Am Coll Cardiol       Date:  2005-12-09       Impact factor: 24.094

5.  Body weight: a risk factor for subtherapeutic antithrombotic therapy in neurovascular stenting.

Authors:  Doniel Drazin; Armen Choulakian; Miriam Nuño; Penelope Kornbluth; Michael J Alexander
Journal:  J Neurointerv Surg       Date:  2010-11-17       Impact factor: 5.836

6.  Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement.

Authors:  Willibald Hochholzer; Dietmar Trenk; Martin F Fromm; Christian M Valina; Christian Stratz; Hans-Peter Bestehorn; Heinz Joachim Büttner; Franz-Josef Neumann
Journal:  J Am Coll Cardiol       Date:  2010-06-01       Impact factor: 24.094

7.  Stenting versus aggressive medical therapy for intracranial arterial stenosis.

Authors:  Marc I Chimowitz; Michael J Lynn; Colin P Derdeyn; Tanya N Turan; David Fiorella; Bethany F Lane; L Scott Janis; Helmi L Lutsep; Stanley L Barnwell; Michael F Waters; Brian L Hoh; J Maurice Hourihane; Elad I Levy; Andrei V Alexandrov; Mark R Harrigan; David Chiu; Richard P Klucznik; Joni M Clark; Cameron G McDougall; Mark D Johnson; G Lee Pride; Michel T Torbey; Osama O Zaidat; Zoran Rumboldt; Harry J Cloft
Journal:  N Engl J Med       Date:  2011-09-07       Impact factor: 91.245

8.  Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.

Authors:  Shlomi Matetzky; Boris Shenkman; Victor Guetta; Michael Shechter; Roy Beinart; Roy Bienart; Ilan Goldenberg; Ilya Novikov; Hanna Pres; Naphtali Savion; David Varon; Hanoch Hod
Journal:  Circulation       Date:  2004-06-07       Impact factor: 29.690

Review 9.  Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives.

Authors:  Dominick J Angiolillo; Antonio Fernandez-Ortiz; Esther Bernardo; Fernando Alfonso; Carlos Macaya; Theodore A Bass; Marco A Costa
Journal:  J Am Coll Cardiol       Date:  2007-03-26       Impact factor: 24.094

10.  Antiplatelet resistance and thromboembolic complications in neurointerventional procedures.

Authors:  Thomas J Oxley; Richard J Dowling; Peter J Mitchell; Stephen Davis; Bernard Yan
Journal:  Front Neurol       Date:  2011-12-26       Impact factor: 4.003

View more
  31 in total

1.  Clopidogrel Resistance in Neurovascular Stenting: Correlations between Light Transmission Aggregometry, VerifyNow, and the Multiplate.

Authors:  N Flechtenmacher; F Kämmerer; R Dittmer; U Budde; P Michels; J Röther; B Eckert
Journal:  AJNR Am J Neuroradiol       Date:  2015-08-13       Impact factor: 3.825

2.  Neurointerventional Stenting and Antiplatelet Function Testing: To Do or Not to Do?

Authors:  Tareq Kass-Hout; Yazan J Alderazi; Krishna Amuluru; Peter Jin; Carlos Ayala; Charles Prestigiacomo; Chirag D Gandhi
Journal:  Interv Neurol       Date:  2015-07

3.  Different Clopidogrel Response Elicited by Lansoprazole or Esomeprazole in Patients Undergoing Neurointervention with Dual Antiplatelet Therapy.

Authors:  Kouhei Nii; Yusuke Morinaga; Takafumi Mitsutake; Ritsurou Inoue; Toshio Higashi
Journal:  Clin Drug Investig       Date:  2019-10       Impact factor: 2.859

4.  Platelet-function testing in patients undergoing neurovascular procedures: caught between a rock and a hard place.

Authors:  J Comin; D F Kallmes
Journal:  AJNR Am J Neuroradiol       Date:  2012-12-20       Impact factor: 3.825

5.  Retrospective Analysis of Delayed Intraparenchymal Hemorrhage after Flow-Diverter Treatment: Presentation of a Retrospective Multicenter Trial.

Authors:  A Benaissa; C Tomas; F Clarençon; N Sourour; D Herbreteau; L Spelle; S Gallas; A-C Januel; A L Gaultier; L Pierot
Journal:  AJNR Am J Neuroradiol       Date:  2015-10-29       Impact factor: 3.825

6.  Choroid artery occlusion after treatment of ICA termination aneurysm: was it caused by stent induced vasospasm?

Authors:  Wilhelm Küker; Ursula Schulz
Journal:  Neuroradiology       Date:  2014-01-21       Impact factor: 2.804

Review 7.  Complications of endovascular treatment for intracranial aneurysms: Management and prevention.

Authors:  Yon Kwon Ihn; Shang Hun Shin; Seung Kug Baik; In Sup Choi
Journal:  Interv Neuroradiol       Date:  2018-02-21       Impact factor: 1.610

Review 8.  Potential Usefulness of Clopidogrel Pharmacogenetics in Cerebral Endovascular Procedures and Carotid Artery Stenting.

Authors:  Jorge Duconge; Dagmar F Hernandez-Suarez
Journal:  Curr Clin Pharmacol       Date:  2017

Review 9.  Aspirin resistance and other aspirin-related concerns.

Authors:  Gaoyu Cai; Weijun Zhou; Ya Lu; Peili Chen; Zhongjiao Lu; Yi Fu
Journal:  Neurol Sci       Date:  2015-11-14       Impact factor: 3.307

10.  Platelet Testing is Associated with Worse Clinical Outcomes for Patients Treated with the Pipeline Embolization Device.

Authors:  W Brinjikji; G Lanzino; H J Cloft; A H Siddiqui; R A Hanel; D F Kallmes
Journal:  AJNR Am J Neuroradiol       Date:  2015-08-06       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.